News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,215 Results
Type
Article (13907)
Company Profile (293)
Press Release (246015)
Section
Business (79450)
Career Advice (147)
Deals (13193)
Drug Delivery (31)
Drug Development (50436)
Employer Resources (31)
FDA (5725)
Job Trends (5159)
News (144421)
Policy (10080)
Tag
Academia (902)
Alliances (21486)
Alzheimer's disease (731)
Approvals (5691)
Artificial intelligence (61)
Bankruptcy (97)
Best Places to Work (4523)
Biotechnology (241)
Breast cancer (58)
Cancer (627)
Cardiovascular disease (52)
Career advice (128)
CAR-T (48)
Cell therapy (157)
Clinical research (39770)
Collaboration (210)
Compensation (86)
COVID-19 (999)
C-suite (60)
Cystic fibrosis (61)
Data (673)
Diabetes (66)
Diagnostics (1222)
Earnings (28843)
Events (46793)
Executive appointments (157)
FDA (5981)
Funding (213)
Gene editing (52)
Gene therapy (130)
GLP-1 (295)
Government (1076)
Healthcare (6552)
Infectious disease (1030)
Inflammatory bowel disease (89)
IPO (7182)
Job creations (860)
Job search strategy (124)
Layoffs (182)
Legal (1374)
Lung cancer (114)
Manufacturing (70)
Medical device (2550)
Medtech (2551)
Mergers & acquisitions (6097)
Metabolic disorders (209)
Neuroscience (914)
NextGen Class of 2024 (1999)
Non-profit (846)
Northern California (837)
Obesity (120)
Opinion (90)
Parkinson's disease (55)
Patents (47)
People (24918)
Pharmaceutical (48)
Phase I (13984)
Phase II (18494)
Phase III (11746)
Pipeline (217)
Postmarket research (847)
Preclinical (5907)
Radiopharmaceuticals (203)
Rare diseases (145)
Real estate (1409)
Regulatory (8231)
Research institute (932)
Southern California (772)
Startups (1963)
United States (6946)
Vaccines (156)
Weight loss (75)
Date
Today (154)
Last 7 days (621)
Last 30 days (1973)
Last 365 days (20708)
2024 (18152)
2023 (22537)
2022 (26928)
2021 (27887)
2020 (23443)
2019 (16284)
2018 (11781)
2017 (13791)
2016 (11889)
2015 (14407)
2014 (10413)
2013 (7501)
2012 (7550)
2011 (7633)
2010 (7442)
Location
Africa (146)
Asia (16861)
Australia (2822)
California (1895)
Canada (673)
China (143)
Colorado (72)
Connecticut (74)
Europe (36216)
Florida (200)
Georgia (55)
Illinois (117)
Indiana (53)
Kansas (55)
Maryland (286)
Massachusetts (1571)
Michigan (46)
Minnesota (85)
New Jersey (517)
New York (561)
North Carolina (385)
Northern California (837)
Ohio (73)
Pennsylvania (390)
South America (207)
Southern California (772)
Texas (192)
Washington State (203)
260,215 Results for "exonics therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Ascidian Therapeutics today announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.
June 18, 2024
·
3 min read
Business
Exonate Appoints Dr Rafiq Hasan as Non-Executive Director
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director.
May 28, 2024
·
2 min read
Business
Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies
Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.
June 18, 2024
·
2 min read
·
Tyler Patchen
Genetown
Ascidian Therapeutics to Present Preclinical Data for RNA Exon Editor, ACDN-01, Supporting an Open IND for Phase 1/2 Clinical Testing at ASGCT 2024 Annual Meeting
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced that it will share preclinical data that enabled IND clearance for Phase 1/2 testing for its lead RNA exon editing therapy, ACDN-01, in a poster session at the American Society of Gene & Cell Therapy (ASGCT) annual meeting in Baltimore, MD, May 7-11, 2024.
April 25, 2024
·
3 min read
Press Releases
ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 24, 2024
·
6 min read
Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal announced new findings from a biomarker study in non-small cell lung cancer patients with exon 20 insertion mutations, highlighting sunvozertinib as an effective treatment for this patient population.
May 24, 2024
·
6 min read
Press Releases
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
November 8, 2024
·
5 min read
Duchenne muscular dystrophy
Dyne Touts ‘Unprecedented’ Dystrophin Expression in Phase I/II DMD Trial for Exon-Skipping Therapy
The highly anticipated results come as the company makes significant changes to its C-suite. Despite the turnover, Dyne said it is looking toward expedited approval pathways for its DMD treatment.
September 3, 2024
·
3 min read
·
Tristan Manalac
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Dizal (SSE:688192) announced today that two abstracts featuring the latest data on sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31 through June 4 in Chicago.
April 24, 2024
·
6 min read
Sunvozertinib’s Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Dizal presented the latest data from the inaugural global pivotal study WU-KONG1 Part B of sunvozertinib in relapsed or refractory non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations at the 2024 American Society of Clinical Oncology Annual Meeting.
June 2, 2024
·
7 min read
1 of 26,022
Next
